Efficacy of forimtamig, a GPRC5DxCD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM) : analysis of patient and disease-related factors associated with responses
(2023)
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA.
In Clinical Lymphoma Myeloma & Leukemia
23(Supplement 2).
p.S3-S4
- Author
- Simon Harrison, Caroline Hasselbalch Riley, Salomon Manier, Sung-Soo Yoon, Antonio Pinto, Titouan Cazaubiel, Anna Guidetti, Rakesh Popat, Cyrille Touzeau, Enrique Ocio, Fritz Offner (UGent) , Paula Rodriguez-Otero, Ilaria Rizzello, Maria-Victoria Mateos, Ann-Marie Broeske, Iryna Dekhtiarenko, Natalie Dimier, Jan Eckmann, Hans-Joachin Helms, Wolfgang Jacob, Meike Schneider, Nassim Sleiman, Martin Weisser and Carmelo Carlo-Stella
- Organization
Downloads
-
(...).pdf
- full text (Published version)
- |
- UGent only
- |
- |
- 137.30 KB
Citation
Please use this url to cite or link to this publication: http://hdl.handle.net/1854/LU-01HPHS48NST3N4CZCTPSBJEMZC
- MLA
- Harrison, Simon, et al. “Efficacy of Forimtamig, a GPRC5DxCD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) : Analysis of Patient and Disease-Related Factors Associated with Responses.” CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, vol. 23, no. Supplement 2, CIG Media Group, LP, 2023, pp. S3–4.
- APA
- Harrison, S., Riley, C. H., Manier, S., Yoon, S.-S., Pinto, A., Cazaubiel, T., … Carlo-Stella, C. (2023). Efficacy of forimtamig, a GPRC5DxCD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM) : analysis of patient and disease-related factors associated with responses. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 23(Supplement 2), S3–S4. CIG Media Group, LP.
- Chicago author-date
- Harrison, Simon, Caroline Hasselbalch Riley, Salomon Manier, Sung-Soo Yoon, Antonio Pinto, Titouan Cazaubiel, Anna Guidetti, et al. 2023. “Efficacy of Forimtamig, a GPRC5DxCD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) : Analysis of Patient and Disease-Related Factors Associated with Responses.” In CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 23:S3–4. CIG Media Group, LP.
- Chicago author-date (all authors)
- Harrison, Simon, Caroline Hasselbalch Riley, Salomon Manier, Sung-Soo Yoon, Antonio Pinto, Titouan Cazaubiel, Anna Guidetti, Rakesh Popat, Cyrille Touzeau, Enrique Ocio, Fritz Offner, Paula Rodriguez-Otero, Ilaria Rizzello, Maria-Victoria Mateos, Ann-Marie Broeske, Iryna Dekhtiarenko, Natalie Dimier, Jan Eckmann, Hans-Joachin Helms, Wolfgang Jacob, Meike Schneider, Nassim Sleiman, Martin Weisser, and Carmelo Carlo-Stella. 2023. “Efficacy of Forimtamig, a GPRC5DxCD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) : Analysis of Patient and Disease-Related Factors Associated with Responses.” In CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 23:S3–S4. CIG Media Group, LP.
- Vancouver
- 1.Harrison S, Riley CH, Manier S, Yoon S-S, Pinto A, Cazaubiel T, et al. Efficacy of forimtamig, a GPRC5DxCD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM) : analysis of patient and disease-related factors associated with responses. In: CLINICAL LYMPHOMA MYELOMA & LEUKEMIA. CIG Media Group, LP; 2023. p. S3–4.
- IEEE
- [1]S. Harrison et al., “Efficacy of forimtamig, a GPRC5DxCD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM) : analysis of patient and disease-related factors associated with responses,” in CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, Athens, Greece, 2023, vol. 23, no. Supplement 2, pp. S3–S4.
@inproceedings{01HPHS48NST3N4CZCTPSBJEMZC,
articleno = {{OA-05}},
author = {{Harrison, Simon and Riley, Caroline Hasselbalch and Manier, Salomon and Yoon, Sung-Soo and Pinto, Antonio and Cazaubiel, Titouan and Guidetti, Anna and Popat, Rakesh and Touzeau, Cyrille and Ocio, Enrique and Offner, Fritz and Rodriguez-Otero, Paula and Rizzello, Ilaria and Mateos, Maria-Victoria and Broeske, Ann-Marie and Dekhtiarenko, Iryna and Dimier, Natalie and Eckmann, Jan and Helms, Hans-Joachin and Jacob, Wolfgang and Schneider, Meike and Sleiman, Nassim and Weisser, Martin and Carlo-Stella, Carmelo}},
booktitle = {{CLINICAL LYMPHOMA MYELOMA & LEUKEMIA}},
issn = {{2152-2650}},
language = {{eng}},
location = {{Athens, Greece}},
number = {{Supplement 2}},
pages = {{OA-05:S3--OA-05:S4}},
publisher = {{CIG Media Group, LP}},
title = {{Efficacy of forimtamig, a GPRC5DxCD3 bispecific antibody, in patients with relapsed/refractory multiple myeloma (RRMM) : analysis of patient and disease-related factors associated with responses}},
volume = {{23}},
year = {{2023}},
}